ArticleTranslational lung cancer research2025
Single-cell and spatial transcriptomics profile the interaction of
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Lipid metabolic reprogramming of tumor-associated macrophages drives resistance to immune checkpoint blockade in lung cancer: a narrative review of mechanisms and therapeutic strategies.Translational lung cancer research · 2026Review
- Innate Immune Cells in Non-Small Cell Lung Cancer: Roles in Tumor Progression and Therapeutic Responses.Cancer innovation · 2026Review
- Functional Depth Biomarkers Distinguish Lung Squamous Cell Carcinoma from Lung Adenocarcinoma.Research square · 2026Article
- C1ORF112 drives lung adenocarcinoma progression through e2f8-mediated transcriptional activation.Journal of thoracic disease · 2026Article
- SPP1-positive myeloid cell subpopulations associated with resistance to PD-1/L1 immunotherapy in lung adenocarcinoma.Scientific reports · 2026Article
- HistoMap: Reconstructing Spatially Resolved Single-Cell Profiles from Bulk RNA-Seq to Decipher the Immune-Excluded Microenvironment in Colon Cancer.International journal of molecular sciences · 2026Article
- Spatial single-cell landscape of tumor-associated macrophages and their crosstalk with the tumor microenvironment.Cell discovery · 2026Article
- ASCL2-mediated macrophage-myofibroblast transition generates immunosuppressive CAF_7 in NSCLC bone metastases.Journal of experimental & clinical cancer research : CR · 2026Article
- A contamination-adjusted tissue thrombopoietic framework identifies a clinically relevant CAF-myeloid niche in non-small cell lung cancer: a paired transcriptomic and survival study.Journal of translational medicine · 2026Article
- Mechanobiology of non-small cell lung cancer: bridging tumor mechanics and therapeutic strategies.Molecular biology reports · 2026Review
- VCAN promotes the progression and recurrence of esophageal squamous cell carcinoma by remodeling the tumor microenvironment.Scientific reports · 2026Article
- Spatiotemporal immune dynamics in lung cancer progression and treatment.Breathe (Sheffield, England) · 2026Review
- The double-edged sword role of tumor-associated macrophages: preventing or causing resistance to immunotherapy.Journal of experimental & clinical cancer research : CR · 2026Review
- SPP1+ Macrophages and the Orchestration of Spatially Organized Immunosuppression in Cancer.Biomedicines · 2026Review
- Article
- Rab37-mediated OPN secretion enriches SPP1Oncogenesis · 2026Article
- CA9+ cancer-associated fibroblasts cooperate with SPP1+ tumor-associated macrophages driving immune resistance in triple-negative breast cancer.Cellular and molecular life sciences : CMLS · 2026Article
- COPD-Lung Cancer Comorbidity: Mechanistic Insights and Precision Oncology Implications.International journal of chronic obstructive pulmonary disease · 2026Review
- Cancer-associated fibroblasts in the lung cancer microenvironment from multi-dimensional mechanisms to therapeutic strategies.Frontiers in oncology · 2026Review
- SPP1 (osteopontin): a key regulator orchestrating cancer progression and non-cancerous pathologies - therapeutic opportunities and future directions.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) remains one of the most prevalent malignancies. A series of differentially expressed genes (DEGs) have been identified in tumor samples and play critical roles in modulating the characteristics of tumor cells. However, some DEGs are specifically expressed in the tumor microenvironment (TME) cells. The underlying mechanisms of the functional DEGs warrant comprehensive investigation to elucidate their contributions to tumor biology of NSCLC. Therefore, the primary goal of our study is to systematically investigate TME-related DEGs using NSCLC as a model. Methods: DEG analysis was performed by comparing bulk transcriptomes of adjacent and tumor samples across 7 independent NSCLC cohorts. Expression pattern of these DEGs were annotated to specific cell types using a single-cell RNA sequencing (scRNA-seq) dataset from 13 NSCLC studies. Myeloid and stromal cells were re-clustered to achieve a detailed characterization of cell-cell interactions within the TME. Spatial co-localization of distinct subpopulations was validated by immunofluorescence staining and spatial transcriptomics (ST). Finally, functional relevance of these interactions was evaluated using a conditional knockout mouse model. Results: A total of 82 overlapping DEGs were screened out using bulk transcriptomes across 7 NSCLC cohorts. After clustering the integrated 547,360 cells from 217 adjacent/tumor NSCLC samples with available scRNA-seq data, we observed that most of these DEGs were specifically expressed in epithelial, myeloid, and stromal cells. Notably, Conclusions:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.